Business & Industry

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.

In early 2026, the White House struck a series of tariff and pricing deals with major pharma firms, linking lower prices for GLP‑1 and other drugs to tariff relief and new distribution channels. Explore how these arrangements are reshaping U.S. pharma pricing, access and global spillovers.

In 2026, GSK, Amgen and other large pharma players restarted the M&A engine with targeted deals in immunology and oncology, signalling a shift toward science‑driven, portfolio‑balancing acquisitions. Explore how this new M&A cycle is reshaping the global pharma landscape.

Global pharma in Q1‑2026 is defined by pricing shocks in the US and Europe and a powerful growth shift to Asia. Explore how policy, margins, M&A and regional strategies are reshaping the pharmaceutical industry.

Egypt is stepping up its push to reinforce its pharmaceutical research landscape by deepening pharmaceutical cooperation with Takeda Pharmaceutical Company, aligning with a wider national agenda to strengthen healthcare capabilities and drug development infrastructure. In this context, the Egyptian Drug...

Swiss drugmaker Roche has expanded its artificial intelligence infrastructure by deploying more than 2,100 NVIDIA chips, strengthening its computational capabilities to accelerate drug and diagnostics development. The move, centred on a large-scale Roche AI factory, reflects the company’s ongoing...

Novartis has received approval from the US Food and Drug Administration (FDA) for Cosentyx (secukinumab) for the treatment of paediatric patients aged 12 years and above with moderate to severe hidradenitis suppurativa (HS). The FDA approval expands the therapy’s...